Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2023-08-11 Interim / Quarterly Rep…
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q2 2023
2023-08-11 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and includes a press release announcing financial results for the quarter ended June 30, 2023. The document states that the press release is furnished as an exhibit and incorporated by reference, indicating this filing is an announcement of financial results rather than the full financial report itself. The length is 9605 characters, which is relatively short and consistent with a report announcing results rather than containing full financial statements or detailed analysis. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2023-08-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or updates by a company. The text references a merger agreement and provides pro forma financial information related to the merger. It explicitly states it is a Current Report on Form 8-K and includes unaudited pro forma financials as an exhibit. The document is not a full annual or quarterly report, nor is it a proxy statement or solicitation. It is an announcement of a significant corporate event (merger) and related financial information. Therefore, the filing type corresponds to Regulatory Filings (RNS), which is the fallback category for miscellaneous filings like Form 8-K that do not fit other specific categories.
2023-08-11 English
425 Filing
M&A Activity Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Pyxis Oncology, Inc. It reports a significant corporate event: the merger agreement with Apexigen, Inc. The document includes detailed descriptions of the merger terms, pro forma financial information related to the merger, and references to exhibits containing unaudited pro forma condensed combined financial statements. The presence of pro forma financials and merger details indicates this is a report about a merger transaction. The document is not a full annual or quarterly report, nor is it a proxy statement or solicitation. It is a current report specifically disclosing a merger event and related financial information. Therefore, the filing type corresponds to M&A Activity (Code: TAR). The document length (15,000 characters) and content confirm it is the report itself, not just an announcement or certification.
2023-08-11 English
425 Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Pyxis Oncology, Inc. dated August 11, 2023. It includes a press release announcing financial results for the quarter ended June 30, 2023, and a corporate update. The document explicitly states it is a "Current Report" pursuant to the Securities Exchange Act of 1934, and the financial results are summarized in the press release (Exhibit 99.1). The content includes detailed financial results for Q2 2023, operational updates, and upcoming milestones. The document is not a full quarterly or annual report but a current report announcing quarterly financial results and corporate updates. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. The document is about 15,000 characters, which is consistent with a detailed earnings release rather than a brief announcement or a full quarterly report. Therefore, the appropriate classification is Earnings Release (ER).
2023-08-11 English
Regulatory Filings 2023
Regulatory Filings
2023-08-01 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.